ChronTech Pharma AB: ChronTech Receives a Six Months’ Extension of Its Option to Buy Back in ChronSeal®

STOCKHOLM--(BUSINESS WIRE)-- As a consequence of that the results of the ChronSeal® study will not be made public until May 27th Kringle Inc. in Japan has given ChronTech Pharma (STO:CTEC) a six months’ extension, i.e. until the 31st of December 2010, of its option to buy back in ownership of the ChronSeal®.

About ChronTech

ChronTech develops the therapeutic DNA vaccines ChronVac-C® and ChronVac-B drugs against chronic hepatitis C virus and hepatitis B virus infections, i.e. chronic infections with jaundice causing viruses which can lead to liver cirrhosis and liver cancer. ChronTech has also developed and further develops a patent pending new type of injection needle for a more effective uptake of DNA vaccines. ChronTech also have part ownership in the wound healing therapy ChronSeal®, and in the new platform technology RAS®. The ChronTech share is admitted to trade on First North. Remium AB is Certified Adviser for ChronTech. For more information, please visit:

In the event of any discrepancy between the Swedish and English versions of this press release, the Swedish version will take precedence.

This information was brought to you by Cision


ChronTech Pharma AB
Anders Vahlne, +46 8 5858 1313
CEO and Head of Research
Mobile phone: +46 709 28 05 28
[email protected]

KEYWORDS:   Europe  Sweden

INDUSTRY KEYWORDS:   Health  Biotechnology  Infectious Diseases  Medical Devices  Pharmaceutical  Other Health  Medical Supplies